期刊文献+

玻璃体腔注射贝伐单抗治疗糖尿病性黄斑水肿疗效观察 被引量:25

Intravitreous bevacizumab(Avastin) therapy for diffuse diabetic macular edema
下载PDF
导出
摘要 目的评估玻璃体腔注射贝伐单抗bevacizumab(Avastin)治疗糖尿病性黄斑水肿(DME)的疗效。方法回顾分析接受玻璃体腔注射Avastin治疗DME的患者57例(68眼),所有患者均接受玻璃体腔内注射Avastin1.25mg(0.05mL)。治疗前及治疗后1、2、3d,3、6、12周进行最佳矫正视力(BCVA)、眼压、裂隙灯及间接检眼镜检查。治疗前及治疗后3、6、12周行光学相干断层扫描(OCT)检查。治疗前及治疗后6周、12周行彩色眼底照相、荧光素眼底血管造影(FFA)检查。有21、13、2眼分别需要注射2、3、4次。随访时间2~19个月,平均(3.10±1.62)个月。对比分析治疗前后患者视力及黄斑中心视网膜厚度(CMT)的改变。结果治疗后患者视力明显提高,CMT平均值治疗前为(506.19±153.78)μm,治疗后3、6、12周时均明显减低(t=3.45,3.18,3.46,P<0.05),治疗后末次随诊时为(379.10±166.32)μm,与术前相比差异有统计学意义(t=4.719,P=0.000)。随访中未见眼压异常改变及白内障的进展,未见与药物有关的眼部和全身不良反应。结论玻璃体腔注射Avastin后,黄斑水肿明显减轻,视力稳定并提高,必要时需要连续注射治疗,长期效果需进一步观察。 Objective Retinal photoeoagulation is beneficial for improving the visual acuity in the patients with macular edema,hut its outcome is not satisfied for diffuse macular edema. This study was to evaluate the efficacy of bevacizumab(Avastin) on diffuse diabetic macular edema. Methods The clinical data of 68 eyes(57 patients) with diffuse maeular edema received intravitreous injection of 1.25 mg (0. 05 mL) bevacizumab (Avastin) were retrospectively analyzed. The best corrected visual acuity(BCVA) , slit-lamp examination,intraocular pressure measurement and stereoscopic biomieroseopy examination were carried out before injection and at 1 day, 2 days, 3 days, 3 weeks, 6 weeks and 12 weeks after initial injection. Optical coherence tomography(OCT) was performed prior to injection and 3,6,12 weeks after initial injection. Fundus photography, fluoreseein fundus angiography(FFA) were performed prior to injection and 6,12 weeks after initial injection. The follow-up period was 2 - 19 months. The changes of BCVA and central macular thickness (CMT) of all the eyes were evaluated before and after the injection. Results The BCVA was improved in 29 eyes (42.6%), stable in 35 eyes (51.5%) and decreased in 4 eyes (5.9%) during the follow-up. The mean central macular thickness was(506.19 + 153.78) μm in preinjection and(379.10 + 166.32)μm in postinjection, showing a statistically significant difference between them (t = 4. 719, P = 0. 000). No significant change in lOP and eataraet progression were observed. No adverse events of ocular or systemic tissue occurred. Conclusion The intravitreal injection of bevacizumab(Avastiu) can relieve diffuse maeular edema and damage of visual function.
出处 《眼科研究》 CSCD 北大核心 2009年第2期118-121,共4页 Chinese Ophthalmic Research
关键词 贝伐单抗 糖尿病视网膜病变 黄斑水肿 bevacizumab(Avastin) diabetic retinopathy macular edema
  • 相关文献

参考文献15

  • 1Klein R, Klein BE, Moss SE. Visual impairment in diabetes[J]. Ophthalmology, 1984,91 : 1 - 9
  • 2Early Treatment Diabetic Retinopathy Study Research Group. Early treatment diabetic retinopathy study report number 1. Photocoagulation for diabetic macular edema [ J ]. Arch Ophthalmol, 1985, 103 ( 12 ) : 1796 - 1806
  • 3Gilliies MC, Kuzniarz M, Craig J, et al. lntravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract[ J ]. Ophthahnology ,2005,112:139 - 143
  • 4钱彤,黎晓新.玻璃体腔注射曲安奈德后的眼压改变[J].中华眼底病杂志,2007,23(2):115-117. 被引量:35
  • 5Nguyen QD, Shah SM,van Anden E,et al. Supplemental oxygen improves diabetic macular edema: a pilot study[J]. Invest Ophthalmol Vis Sci, 2004,45: 617 - 624
  • 6Ferrara N. Vascular endothelial growth factor: basic science and clinical progress[J]. Endocr Rev ,2004,25: 581 - 611
  • 7Mordenti J, Thomsen K, Licko V, et al. Intraocular pharmacokinetics intravitreal administration of a solution or a PLGA microsphere formulation [J]. Toxicol Sci,1999,52:101 - 106
  • 8Shahar JS, Avry RL, Heilweil G, et al. Eleetrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab[J]. Retina ,2006,26: 262 - 269
  • 9Rosenfeld PJ, Moshfeghi AA,Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab(Avastin)for neovascular age-related macular degenerationIJ]. Ophthalmic Surg Lasers Imag,2005,36: 331 - 335
  • 10Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration[ J]. Ophthalmology ,2006,113 : 363 - 372

二级参考文献11

  • 1王景昭.黄斑水肿的药物和手术治疗[J].中华眼底病杂志,2004,20(5):316-319. 被引量:26
  • 2McCuen BW 2^nd, Bessler M, Tano Y, et al. The lack of toxicity of intravitreally administered triacinolone acetonide. Am J Ophthalmol, 1981,91 : 785-788.
  • 3Hida T, Chandler D, Arena JE, et al. Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol, 1986, 101 : 190-195.
  • 4Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol, 2003,87:24- 27.
  • 5Jonas JB, Kreissig I, Degenring R. Secondary chronic openangle glaucoma after intravitreal triamcinolone acetonide. Arch Ophthalmol, 2003,121 : 729-730.
  • 6Penfold PL, Gyory JF, Hunyor AB, et al. Exudative macular degeneration and intravitreal triamcinolone: a pilot study. Aust N Z J Ophthalmol, 1995,23:293-298.
  • 7Gilliies MC, kuzniarz M, Craig J, et al. Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract.Ophthalmology, 2005,112 : 139-143.
  • 8Audren F, Tod M, Massion P, et al. Pharmacokinetic pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema. Invest Ophthalmol Vis Sci, 2004, 45: 3435-3441.
  • 9Jonas JB, Degenring R, Kreissig I, et al. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection.Ophthalmology, 2005,112 : 593-598.
  • 10Smithen LM, Ober MD, Maranan L, et al. Intravitreal triamcinolone acetonide and intraocular pressure. Am J ophthalmol, 2004,138 : 740-743.

共引文献34

同被引文献262

引证文献25

二级引证文献121

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部